Founded in 2014, GreenLight Medicines is a biopharmaceutical company focused on researching, developing and selling medicines from proprietary cannabinoid formulations in a range of disease areas.
Within a new era of pharmaceutical development, GreenLight is developing new plant-derived cannabinoid medicines from proprietary whole-plant strains. Its intellectual property portfolio is based on proprietary blends of cannabinoid oils, as well as novel plant oil extraction processes.
The main goal is to create a major European Centre of Excellence for plant-based medicines through the integration model of academic and commercial research and development.
GreenLight has structured itself as a pharmaceutical company covering all aspects of drug development.
The GreenLight service offering includes:
Research and development
- Plant technology, plant genetics
- Regulatory and compliance
- Product definition and evaluation
- A multi-disciplined research team in:
Project development clinical research
- Early stage research
- Pre-clinical research
- Phase 1
- Late stage clinical trial
- Phase 2, 2a
- Phase 3-4
- NDA to pharma (packaged for FDA/EMEA approval)
- Consultancy in:
- Material cultivation and extraction
- Material analysis
- Material import
- Food supplements sales and distribution
GreenLight Medicines strives to create awareness within our industry, as well as develop environmentally friendly and sustainable medicines, all whilst increasing our shareholder value by developing new markets for our medicines and with the aim of creating as many as 500 research and development jobs in the next five years.
To be part of this journey and to invest in GreenLight Medicines, please contact us at firstname.lastname@example.org.
GreenLight Medicines and university partnerships
GreenLight Medicines has established numerous relationships with high-level academic institutions across the globe.
By combining our cannabis and pharmaceutical expertise with the academic knowledge and research infrastructure already in place in universities, we can quickly research cannabinoids and other plant components across a wide spectrum of diseases.
As a result, GreenLight Medicines is on course to become a world leader in medical cannabis research.